Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B‐cell non‐Hodgkin lymphoma

As CD20 has become an established target for treating B‐cell malignancies, there is interest in developing anti‐CD20 antibodies with different functional activity from rituximab that might translate into improved efficacy. Obinutuzumab (GA101) is a glycoengineered, humanized type II anti‐CD20 monocl...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancer Sci
Главные авторы: Ogura, Michinori, Tobinai, Kensei, Hatake, Kiyohiko, Uchida, Toshiki, Suzuki, Tatsuya, Kobayashi, Yukio, Mori, Masakazu, Terui, Yasuhito, Yokoyama, Masahiro, Hotta, Tomomitsu
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2012
Предметы:
Original Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7657177/
https://ncbi.nlm.nih.gov/pubmed/23046388
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12040
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы